Upstream Bio, Inc. Common Stock UPB
HEALTHCARE · BIOTECHNOLOGYi
Market datapartial · fetched 2026-11-06T21:19:54.392Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T21:00:00.282350306Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-06T21:13:21.377558+00:00
Upstream Bio, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 2.87 | 348.1% | 48.0% | |||
| 30Δ | 3.27 | 331.9% | 42.8% | |||
| 35Δ | 3.66 | 315.6% | 37.7% | |||
| 40Δ | 4.06 | 299.4% | 32.5% | |||
| 45Δ | 4.46 | 283.1% | 27.3% | |||
| 50Δ | 4.86 | 266.8% | 22.1% | |||
| 55Δ | 5.34 | 256.9% | 18.5% | |||
| 60Δ | 5.88 | 250.5% | 15.6% | |||
| 65Δ | 6.42 | 244.2% | 12.8% | |||
| 70Δ | 6.96 | 237.8% | 9.9% | |||
| 75Δ | ||||||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.87
- IV
- 348.1%
- B/E move
- 48.0%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.27
- IV
- 331.9%
- B/E move
- 42.8%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.66
- IV
- 315.6%
- B/E move
- 37.7%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.06
- IV
- 299.4%
- B/E move
- 32.5%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.46
- IV
- 283.1%
- B/E move
- 27.3%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.86
- IV
- 266.8%
- B/E move
- 22.1%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.34
- IV
- 256.9%
- B/E move
- 18.5%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.88
- IV
- 250.5%
- B/E move
- 15.6%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.42
- IV
- 244.2%
- B/E move
- 12.8%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.96
- IV
- 237.8%
- B/E move
- 9.9%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
No recorded observations
Biotechnology
URGN
UroGen Pharma Ltd (URGN) is an innovative biotechnology company focused on the development of advanced therapies for urological diseases, including urothelial carcinoma and…
More →VANI
Vivani Medical Inc. (VANI) is a pioneering biotechnology firm focused on revolutionizing chronic disease management through its cutting-edge drug delivery systems. The company…
More →VCEL
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cell therapies for the sports medicine and severe burn care…
More →VERA
Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases in the United…
More →VERU
Veru Inc., an oncology biopharmaceutical company, focuses on the development of drugs for the treatment of cancers. The company is headquartered in Miami, Florida.
More →VIR
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. The company is headquartered in San…
More →